Related Experiment Video
Updated: Apr 22, 2026
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
AML genomics for the clinician
Timothy Graubert1, Richard Stone2
1Massachusetts General Hospital Cancer Center, Boston, MA.
Abstract:
Acute myeloid leukemia (AML) is a heterogeneous disease, characterized by frequent resistance to available chemotherapeutic agents. The basic therapy for patients with AML has changed little over the past 30 years. Improvements in outcome in recent decades in younger adult cohorts have generally been ascribed to better supportive care (ie, transfusion and antimicrobial therapy); older adults with AML continue to fare poorly. The explosion of new knowledge regarding the AML genome has yet to be translated into therapeutic benefit, but analysis of specific molecular features in AML samples has enabled the field to more accurately parse out prognosis and assign appropriate therapies (eg, chemotherapy vs allogeneic stem cell transplantation) for groups of patients. Cytogenetic analysis, whether by metaphase or interphase analysis, has been the main tool used to divide patients into varying prognostic subsets, but it has been modified in recent years to include assessment of mutations in a small number of genes. In the past several years, new technologies have provided strategies to interrogate individual cancer genomes in a broad and in-depth fashion. The present article discusses the potential of these new technologies, particularly gene panel and whole-exome or whole-genome sequencing, to improve diagnosis, prognosis, and therapeutic outcome in AML.
Insights
New genomic sequencing technologies offer hope for improving acute myeloid leukemia (AML) treatment. These advanced methods can enhance diagnosis and prognosis, potentially leading to better therapeutic outcomes for AML patients.
Area of Science:
- Hematology
- Genomics
- Oncology
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer with limited treatment advancements over 30 years.
- Current AML therapies show poor outcomes, especially in older adults, despite improved supportive care.
- Genomic insights into AML have improved prognosis and therapy selection, but clinical translation remains a challenge.
Purpose of the Study:
- To discuss the potential of novel genomic technologies in acute myeloid leukemia (AML).
- To explore how gene panel and whole-exome/genome sequencing can advance AML diagnosis and prognosis.
- To highlight the prospective impact of these technologies on therapeutic outcomes in AML.
Main Methods:
- Review of recent advancements in genomic interrogation technologies.
- Discussion of gene panel sequencing, whole-exome sequencing, and whole-genome sequencing applications.
- Analysis of how these technologies can refine AML patient stratification and treatment selection.
Main Results:
- Genomic analysis, including cytogenetics and mutation assessment, aids in prognostication.
- New sequencing technologies provide in-depth interrogation of individual cancer genomes.
- These technologies hold promise for more precise diagnosis and personalized therapy in AML.
Conclusions:
- Advanced genomic sequencing technologies are poised to revolutionize AML management.
- Improved diagnostic and prognostic capabilities can lead to better-tailored therapeutic strategies.
- The integration of comprehensive genomic profiling is crucial for advancing AML patient care and outcomes.
More Related Videos
09:37Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Related Concept Videos
02:02Genomics
01:29Pharmacogenomics: Identification of New Drug Targets
01:29Pharmacogenetics and Pharmacogenomics: Overview
01:29Modern Molecular Taxonomy